Emerging Diabetes Technology Driven By Patient Demands

Integration has become a key driver in the development of a new wave of diabetes tools that have either recently hit the market or will become available in the next few years. Many diabetics, who have a great deal of influence on the success or failure of products in this space, are seeking devices that work seamlessly with the smart phones and cellular technology that are so prevalent today. A number of start-up companies are poised to compete with the bigger diabetes manufacturers as the market continues to evolve.

Developing a successful device in the diabetes market requires paying attention to what patients want. Although physicians are naturally a key source of information, diabetics are not only very active, but also can be extremely demanding about what they want, need, and will use. Younger diabetics brought up in the internet age are a particularly vocal group, and they have learned to use social media to band together and make their opinions heard. A manufacturer that wants to develop a diabetes product that will be in demand must listen to what patients are requesting. In many ways the things diabetics are asking for are not hard to understand; they want less invasive/pain-free methods of testing glucose levels and delivering insulin and devices that take advantage of ongoing information technology advances to record and track their glucose readings.

Products that reflect this trend have already begun entering the market, including products from companies with technologies that tap into the pervasive wireless and mobile capabilities currently touching nearly every industry. Bluetooth technology has been incorporated into several models of glucose meters to transmit data wirelessly to a patient’s smart phone or computer. However, one start-up company has taken the use of wireless technology a step further and created the first cellular enabled-glucometer that transmits data directly and automatically to a database

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

23andMe Purchase Will Let Regeneron Scale Drug Development

 

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Disparities — Including Financials Shortcomings — Remain In Women’s Health, Execs Say

 

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.

Debate On FDA User Fee Reauthorization Begins To Take Shape

 
• By 

A battle may be forming over the 2027 FDA user fee reauthorizations. At a conference Friday, Democratic Rep. Jake Auchincloss supports them for their effectiveness, while Deputy FDA Commissioner Grace Graham echoed criticisms from HHS Sec. Kennedy, among others, in calling for reform to ensure public trust.

More from North America

Health Secretary Defends Spending Cuts During Senate Hearing On HHS Budget

 
• By 

Health and Human Services Secretary Robert F. Kennedy Jr. emphasized administrative cost reductions and defended budget decisions during a Senate hearing on HHS funding. Some senators, however, expressed concerns over the impacts spending cuts had on essential health programs.

Tariffs Threaten Medtech Innovation And US Position As World Leader, Whitaker Tells Lawmakers

 

During his testimony before US senators on the impact of tariffs on critical supply chains, AdvaMed’s Scott Whitaker said the Trump tariffs could jeopardize America’s preeminence in medtech. Other industry experts echoed similar concerns.

Califf Warns Progress May Be In Danger Due To ‘Decimated’ FDA Staff

 

In Vivo spoke to the previous commissioner of the US FDA about recent ongoings at the agency, and where he believes policy should be directed for patient and industry benefit.